Mannkind Corporation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Mannkind Corporation

MNKD 5.625

-1.3%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Savant	5/19/2015 9:54:01 AM
	of 84

Analysts at Jefferies issued a note last Friday morning saying they see "good interest" for use of MannKind's (NASDAQ: MNKD) Afrezza drug. Afrezza, the company's signature drug, is an inhalable product to treat diabetes. The firm reiterated its "buy" rating with a price target of $9 following its recent Afrezza surve

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next